Another disappointing quarterly. $116k sales is not what the company was portraying.
They are so good at spruiking.
At least they are consistent.
This was the market update on 27th April :
Covid-19 Environment drives demand for Oventus devices
Key highlights:
• Interest in Oventus oral devices is being driven by concern regarding CPAP’s potential
role in spreading COVID-19 virus through aerosol droplets
• Four contracted sites now scheduled to launch remotely during April, taking total
number of sites launched to 18
• Contracts signed in Canada for two new clinical sites, taking total contracted sites under
Oventus’ Lab in Lab model to 45
• Telehealth extension to Lab in Lab business model operating efficiently; building
pipeline of patient bookings
• Patient bookings since mid-March, when the gravity of the COVID-19 pandemic started
to crystallise for the US and Canada, have now exceeded total February patient bookings
Then the next day a large cap raising.
I am holding my tongue.
- Forums
- ASX - By Stock
- Ann: Quarterly Business Review & Appendix 4C
Another disappointing quarterly. $116k sales is not what the...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OVN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online